What to Expect at a Psilocybin Session

A psilocybin-assisted therapy session is a structured 6–8 hour clinical day. Most patients arriving for their first session have read about the medicine but want to know what the day actually looks like — what to wear, what to bring, what the dosing room looks like, what the peak feels like, when they can go home, and what the next day is like. This article walks through it in the order it happens, drawing on published trial protocols (Carhart-Harris 2016, Davis 2021, Goodwin 2022, Bogenschutz 2022) and on the standards used by SAP-pathway Canadian providers. Two important compliance reminders: psilocybin is Schedule III with no Health Canada approved indication, accessed only through the Special Access Program (SAP) via your prescribing physician; this article describes the clinical session structure, not how to obtain psilocybin outside SAP.

Key takeaways

• The dosing day is 6–8 hours total in clinic — arrival, vitals, dosing, peak experience (1.5–3 hours), comedown, recovery, discharge.
• Onset is 20–50 minutes after taking the dose. Peak intensity is at 1.5–3 hours. Effects resolve over 4–6 hours total.
• Two trained therapists are present in most published trial protocols. Eye shades and curated music are standard.
• You cannot drive home. A designated driver is required. Plan to rest at home for the remainder of the day.
• Common physical sensations: pupil dilation, mild blood pressure elevation, body temperature changes, mild nausea, fatigue afterward.
• Common experiential phenomena: visual changes, time distortion, emotional intensity, ego dissolution at higher doses, mystical-type experience (oceanic boundlessness), challenging moments.
• Integration sessions in the days and weeks afterward are where the experience becomes change.

Before the day — preparation

Preparation begins 2–4 weeks before the dosing session, with 2–3 dedicated preparation sessions with your therapy team. By the time the dosing day arrives, you have:

• Met the therapy team who will be present during dosing. Continuity of presence matters.
• Reviewed your history, intentions, and what you hope the work will address.
• Practiced grounding skills for navigating moments of acute anxiety or challenging content.
• Previewed the music in some protocols (sampling the playlist in advance reduces anxiety).
• Signed informed consent including off-label / SAP framing, expected effects, known risks.
• Arranged a designated driver for after the session.
• Planned post-session rest for the remainder of the day.

For the therapeutic-frame deep dive, see How Psilocybin-Assisted Psychotherapy Works.

Day-before prep

The 24 hours before dosing typically include:

• Light meal in the evening; light breakfast on the day if instructed by your team — some protocols prefer fasting that morning to reduce nausea risk. Follow your specific clinical team's guidance.
• Avoid alcohol, cannabis, and recreational substances for 24–48 hours before.
• Hold specific medications under prescriber supervision — many protocols taper SSRIs/SNRIs in advance, and some protocols hold benzodiazepines on dosing day (these may attenuate effect).
• Sleep well.
• Bring the day's items: a comfortable change of clothes, a journal, water, perhaps a meaningful object (some patients bring a photo or small object that anchors them).

Arrival — the first ~15 minutes

You arrive at the clinic, typically in the morning. Standard elements of the first 15 minutes:

• Check-in and orientation to the dosing room.
• Confirmation that you have a designated driver arranged for departure.
• Final medical review: blood pressure, heart rate, oxygen saturation. ECG if not already on file.
• Final review of consent and review of what the day will look like.
• Settling in: changing into comfortable clothes if preferred, lying down on the dosing couch or bed, blanket, eye shades available.

The room is typically warm, softly lit, aesthetically curated — not a clinical examination room. Some clinics use small touches like fresh flowers or art that supports a calm aesthetic.

Dose administration

The dose is taken orally — typically a capsule of synthetic psilocybin. The published trial standard for TRD work is 25 mg (Goodwin 2022 COMP001 protocol); cancer trials used 22 or 30 mg per 70 kg (Griffiths 2016) or 0.3 mg/kg (Ross 2016). Your specific dose depends on the SAP-authorized protocol your prescribing physician has documented.

Dose administration takes a few minutes. After taking the dose, you settle into the dosing position — most patients lie down with eye shades and music begins.

Onset (20–50 minutes after dose)

Effects begin gradually. The first awareness is often:

• Mild perceptual changes: colours feel slightly more saturated, patterns feel more present.
• Body sensations: mild changes in body temperature, sometimes a sense of energy or tingling.
• Emotional opening: a sense of vulnerability, occasionally mild anxiety as the experience builds.
• Time distortion beginning to emerge.

The therapy team is primarily quiet during onset, present and available but not actively engaging. Most patients settle inward.

Peak (1.5–3 hours after dose)

This is the most intense phase. Common phenomena:

• Visual changes: with eyes closed, geometric patterns, colour fields, sometimes vivid imagery. With eyes open (less common during peak), enhanced colour and pattern perception.
• Time distortion: profound. Minutes feel like hours; hours feel like minutes.
• Emotional intensity: amplification of underlying feelings — joy, sadness, fear, gratitude, grief. Often rapidly shifting.
• Ego dissolution: at higher doses, the sense of being a bounded self may temporarily soften or dissolve. This can be profoundly meaningful for many patients and momentarily disorienting for some.
• Mystical-type experience: oceanic boundlessness, sense of unity, transcendence of time/space, sacredness, noetic quality (a "knowing" beyond cognitive understanding). The Mystical Experience Questionnaire (MacLean, Johnson, Griffiths 2011) is the standard psychometric instrument; mystical experience intensity correlates with therapeutic outcomes (Roseman 2018).
• Insights: many patients report sudden clarity about life situations, relationships, patterns they've struggled with.
• Challenging moments: fear, body horror, grief, disorientation. These are common and often productive — therapy team holds non-directive presence; integration session afterward is where challenging content becomes meaningful.

The therapy team practices non-directive presence — physically available, energetically supportive, not interpreting or actively talking. Patients can speak with the team if they want; many choose to remain inward.

For the experiential framing more broadly, see What Is Psilocybin Therapy?.

Comedown (3–5 hours after dose)

The intensity gradually subsides. The eye shades typically come off; the patient often spontaneously begins talking; the therapy team becomes more conversational.

• Emerging meaning-making: patients often start articulating what came up, what felt important, what was unexpected.
• Physical settling: heart rate and blood pressure return to baseline; visual changes resolve.
• Fatigue: many patients feel emotionally exhausted in a meaningful rather than depleted way.
• Often hungry — light food is typically available.

The therapy team supports light initial integration — capturing themes, emotions, images that arose. Deeper integration is for the structured integration sessions in the following days.

Discharge (~6–8 hours after arrival)

Standard discharge:

• Final vitals check: blood pressure, heart rate.
• Confirmation of stable mental status: oriented, communicative, not acutely distressed.
• Brief debrief: any immediate concerns, integration session scheduling, contact for the team.
• Designated driver: confirmed pickup; you do not drive yourself.

You leave clinic 6–8 hours after arrival.

At home — the rest of the day

The remainder of the dosing day is rest. Standard guidance:

• No driving for at least 24 hours.
• No alcohol, cannabis, or recreational substances for at least 24 hours (longer where appropriate).
• Light food and hydration.
• Quiet activity: many patients journal; some prefer silence; some watch nature.
• Avoid major decisions for the next 24 hours — emotional intensity can lead to impulsive commitments that might be reconsidered after rest.

The day after and the week ahead

Most patients describe the day after as a period of continued openness — emotions are accessible, insights from the previous day are still present, sometimes with a kind of post-experience tenderness. This is part of the therapeutic window.

Your first integration session is typically within 24–72 hours of dosing. Subsequent integration sessions across the following weeks support translation of the experience into life change.

The honest framing: the dosing day is the beginning of the therapeutic work, not the end. Patients who skip integration generally see less durable change than those who complete the structured frame.

What's normal versus what to flag

Normal during and after the session:

• Visual and perceptual changes during peak
• Time distortion
• Emotional intensity (including challenging emotions)
• Ego dissolution at higher doses
• Mild blood pressure elevation
• Mild nausea, especially early in onset
• Fatigue afterward
• Continued emotional openness for hours-to-days

Flag urgently to your clinic or prescribing physician:

• Sustained elevated blood pressure (e.g., ≥160/100 mmHg) not resolving 1–2 hours after session end
• Persistent disorientation more than 4–6 hours after session end
• Severe persistent headache
• Chest pain, shortness of breath, palpitations
• Suicidal ideation that emerges or worsens
• Severe anxiety that does not resolve within 24 hours
• Persistent visual changes lasting days (rare; HPPD context — see Psilocybin Side Effects and Safety)

For acute psychiatric crisis, call 9-8-8 (Canada Suicide Crisis Helpline) or go to your nearest emergency department.

Frequently asked questions

How long does the session last? 6–8 hours total in clinic. Onset is 20–50 minutes after the dose; peak is 1.5–3 hours; comedown is 3–5 hours; total experience is 4–6 hours plus initial settling and post-session observation.

What should I wear? Comfortable clothes you can lie down in. Layers help — body temperature shifts during the experience. Some patients change into more comfortable clothes upon arrival.

Can I bring something meaningful? Yes. Many patients bring a photo, a small object, or a journal. The therapy team will let you know what's appropriate for the specific clinical setting.

What does the music sound like? Curated playlists are standard — typically classical, ambient, electronic, or world music selected to support the arc of the experience. The "Hopkins playlist" is widely used or adapted across clinical sites.

Do I have to wear the eye shades? Most protocols use eye shades during peak intensity to deepen inward focus. You can typically remove them during comedown or if you prefer not to use them.

What if I need to use the bathroom? Bathrooms are accessible. The therapy team will support you there if needed during peak.

Will I be able to talk? Yes, but most patients spend most of peak intensity inward. The team is available if you want to share, ask, or be grounded.

Will I remember everything? Most patients remember the experience clearly, though the recall may have a non-linear or symbolic quality. Integration sessions help convert experience into language and meaning.

What if I have a difficult experience? Difficult experiences are common and often productive. The therapy team holds non-directive presence; integration sessions are where challenging content becomes meaningful. See Psilocybin Side Effects and Safety.

Why can't I drive? Residual effects on perception, judgment, and reaction time persist for hours after the acute experience subsides. The 24-hour no-driving rule is universal across published clinical protocols.

When do I do integration? The first integration session is typically 24–72 hours after dosing. 2–4 integration sessions follow over the following weeks.

Can my partner or family attend? Most published protocols use therapist-only support during dosing. Some clinical settings accommodate family presence in specific roles, particularly for end-of-life work. Discuss at intake.

What if I don't have a designated driver? You cannot do the session without arranged transport home. Rideshare with a known person, family/friend, or hospice transport (where applicable) are alternatives. Public transit alone is not appropriate.

Sources

1. Goodwin GM, et al. (2022). COMP360 psilocybin in TRD Phase 2b. NEJM. https://pubmed.ncbi.nlm.nih.gov/36322843/
2. Griffiths RR, et al. (2016). Psilocybin in life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909164/
3. MacLean KA, Johnson MW, Griffiths RR (2011). Mystical Experience Questionnaire. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/21674151/
4. Roseman L, Nutt DJ, Carhart-Harris RL (2018). Quality of acute experience predicts efficacy. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/29387009/
5. Carbonaro TM, et al. (2016). Survey of challenging experiences with psilocybin. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27578767/
6. Government of Canada — 9-8-8 Suicide Crisis Helpline: https://988.ca/

Related articles

• Psilocybin Therapy in Canada
• What Is Psilocybin Therapy?
• How Psilocybin-Assisted Psychotherapy Works
• Psilocybin Side Effects and Safety
• How to Access Psilocybin Therapy in Canada (SAP)
• Find care near you

Last updated: 2026-05-06